Video

Next-Generation Sequencing Analysis of Circulating Tumor DNA

Author(s):

Oliver Zill
Conference|ASCO Annual Meeting

Oliver Zill, data scientist, Guardant Health, discusses the somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.

Oliver Zill, data scientist, Guardant Health, discusses the somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.

In the analysis, it was also found that the positive predictive value for finding actionable variance is high across key biomarkers, Zill explains. Researchers are also detecting actionable emerging resistance via circulating tumor DNA, which usually emerges after a patient undergoes a biopsy.

Related Videos
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS
Charles E. Geyer, Jr., MD
Sattva S. Neelapu, MD
Related Content
Lynn M. Schuchter, MD, of Penn Medicine
July 16th 2024

ASCO 2024 Data Shake Up Standards and Shed Light on Biomarkers

Barbara Jane O’Brien, MD, of The University of Texas MD Anderson Cancer Center
June 21st 2024

Tucatinib-Based Regimen Improves Target Deficits, QOL in HER2+ Breast Cancer With Leptomeningeal Metastasis

Allison Graeter, MD
June 12th 2024

Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies

Luis G. Paz-Ares, MD, PhD, chair, Medical Oncology Department, Hospital Universitario 12 de Octubre; associate professor, Universidad Complutense de Madrid
June 11th 2024

Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC

Lakshmi Nayak, MD, director, Center for CNS Lymphoma, Dana-Farber Cancer Institute; associate professor, neurology, Harvard Medical School
June 11th 2024

Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas

Craig E. Devoe, MD, MS
June 11th 2024

Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC